INT23376

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1985
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 7
Disease Relevance 2.59
Pain Relevance 3.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lyase activity (NPL) carbohydrate metabolic process (NPL) cytoplasm (NPL)
Anatomy Link Frequency
tubes 1
NPL (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 46 100.00 Very High Very High Very High
Dopamine 3 100.00 Very High Very High Very High
fluoxetine 7 99.00 Very High Very High Very High
qutenza 47 95.84 Very High Very High Very High
Nerve growth factor 49 90.68 High High
Enkephalin 1 84.48 Quite High
headache 1 83.64 Quite High
Opioid 9 82.44 Quite High
Angina 1 81.48 Quite High
Catecholamine 2 75.00 Quite High
Disease Link Frequency Relevance Heat
Frailty 20 98.84 Very High Very High Very High
Congenital Anomalies 4 91.92 High High
Muscle Weakness 2 90.76 High High
Hypopituitarism 2 89.60 High High
Fatigue 1 84.00 Quite High
Headache 1 83.64 Quite High
Dizziness 1 83.24 Quite High
Angina 1 81.48 Quite High
Hoarseness 1 81.00 Quite High
Stress 1 60.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fluoxetine produced a small but non-significant increase in Nal-stimulated ACTH and cortisol release in both morning and afternoon studies.
Localization (release) of Nal associated with narcan and fluoxetine
1) Confidence 0.47 Published 1997 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 9171947 Disease Relevance 0.06 Pain Relevance 1.12
Naloxone (Nal)-mediated CRH release causes ACTH release in normal humans and an ACTH hyperresponse in DM.
Localization (release) of Nal associated with frailty and narcan
2) Confidence 0.43 Published 1998 Journal J. Neuroendocrinol. Section Abstract Doc Link 9663654 Disease Relevance 0.90 Pain Relevance 0.29
Despite this DM patients have a relative resistance to APZ inhibition of Nal-induced ACTH/cortisol release.
Localization (release) of Nal associated with frailty and narcan
3) Confidence 0.43 Published 1998 Journal J. Neuroendocrinol. Section Abstract Doc Link 9663654 Disease Relevance 1.16 Pain Relevance 0.39
Concurrent treatment with triiodothyronine (T3) 10(-7) M significantly decreased NAL stimulated secretion of TSH and its subunits.
Localization (secretion) of NAL associated with narcan
4) Confidence 0.14 Published 1985 Journal Acta Endocrinol. Section Abstract Doc Link 2412379 Disease Relevance 0 Pain Relevance 0.58
Furthermore, L-NAME and Nal offset the enhanced release of NO caused by pretreatment with morphine.
Localization (release) of Nal
5) Confidence 0.11 Published 2008 Journal Chin. Med. J. Section Body Doc Link 18713554 Disease Relevance 0 Pain Relevance 0
The subject’s head was tilted back and after approximately 10 sec the head was raised and NAL expelled into a collecting basin, measured for volume, and then transferred into conical tubes.
Localization (transferred) of NAL in tubes
6) Confidence 0.09 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1257644 Disease Relevance 0.47 Pain Relevance 0.54
In contrast to the LHRH response, the basal release rate and hourly output as well as NAL-induced DA release from the MBH-POA of intact and castrated rats were similar.
Localization (release) of NAL-induced associated with dopamine and narcan
7) Confidence 0.00 Published 1987 Journal Endocrinology Section Abstract Doc Link 3536452 Disease Relevance 0 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox